News und Analysen
Here's the Best Dividend Stock in Big Pharma
Dividends make a huge impact on your overall investing returns. They can also provide solid income during your retirement years. Historically, big pharma stocks have been a great place for....
Here's the Best Dividend Stock in Big Pharma
Dividends make a huge impact on your overall investing returns. They can also provide solid income during your retirement years. Historically, big pharma stocks have been a great place for....
Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market....
Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market....
Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market....
3 Charts That Show Why Aurinia Pharmaceuticals Stock Could Go Higher
Aurinia Pharmaceuticals (NASDAQ: AUPH) stock is without question one of the best-performing biotech stocks so far in 2017. Shares of the red-hot biotech have tripled in price year to date. Aurinia....
94% of Americans Support Legalizing Medical Marijuana, but Not Congress
When it comes to the fastest, most consistently growing industries in the U.S. right now, legal marijuana is near the top of the list. Investment firm Cowen & Co. has predicted that U.S. legal....
3 Biotech Stocks That Skyrocketed This Week
If you like excitement, biotech stocks provided plenty of it over the last several days. And most of the buzz stemmed from the $11.9 billion buyout of Kite Pharma (NASDAQ: KITE) announced by....
3 Biotech Stocks That Skyrocketed This Week
If you like excitement, biotech stocks provided plenty of it over the last several days. And most of the buzz stemmed from the $11.9 billion buyout of Kite Pharma (NASDAQ: KITE) announced by....
3 Biotech Stocks That Skyrocketed This Week
If you like excitement, biotech stocks provided plenty of it over the last several days. And most of the buzz stemmed from the $11.9 billion buyout of Kite Pharma (NASDAQ: KITE) announced by....
3 Reasons Intuitive Surgical, Inc. Stock Could Rise
In a previous article, I laid out the bear case against Intuitive Surgical (NASDAQ: ISRG). Today, I'm looking at some ways the robotic surgery leader's stock could trend higher in the years....
3 Reasons Intuitive Surgical, Inc. Stock Could Rise
In a previous article, I laid out the bear case against Intuitive Surgical (NASDAQ: ISRG). Today, I'm looking at some ways the robotic surgery leader's stock could trend higher in the years....
3 Reasons Intuitive Surgical, Inc. Stock Could Rise
In a previous article, I laid out the bear case against Intuitive Surgical (NASDAQ: ISRG). Today, I'm looking at some ways the robotic surgery leader's stock could trend higher in the years....
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences (NASDAQ: GILD) has wanted to be a leader in cancer treatment for awhile, and this week, it made a big splash into the indication when it announced the planned acquisition of Kite....
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences (NASDAQ: GILD) has wanted to be a leader in cancer treatment for awhile, and this week, it made a big splash into the indication when it announced the planned acquisition of Kite....
Gilead Sciences’ Oncology M&A Strategy Explained
Gilead Sciences (NASDAQ: GILD) has wanted to be a leader in cancer treatment for awhile, and this week, it made a big splash into the indication when it announced the planned acquisition of Kite....
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
The next big thing in cancer treatment could be chimeric-antigen receptor T-cell therapy, or CAR-T, a novel approach that uncloaks cancer cells so that the immune system can destroy them. The....
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
The next big thing in cancer treatment could be chimeric-antigen receptor T-cell therapy, or CAR-T, a novel approach that uncloaks cancer cells so that the immune system can destroy them. The....
Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
The next big thing in cancer treatment could be chimeric-antigen receptor T-cell therapy, or CAR-T, a novel approach that uncloaks cancer cells so that the immune system can destroy them. The....
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Two of the biggest pharmaceutical companies in the world have been around since the 19th century. Eli Lilly and Company (NYSE: LLY) was founded in 1876, while Pfizer Inc. (NYSE: PFE) began....
Better Buy: Eli Lilly and Company vs. Pfizer Inc.
Two of the biggest pharmaceutical companies in the world have been around since the 19th century. Eli Lilly and Company (NYSE: LLY) was founded in 1876, while Pfizer Inc. (NYSE: PFE) began....
3 Stocks That Pay You
Other than the obvious reason that investors like the steady stream of income that comes from investing in dividend-paying stocks, the stability it conveys about a particular business provides a....
3 Stocks That Pay You
Other than the obvious reason that investors like the steady stream of income that comes from investing in dividend-paying stocks, the stability it conveys about a particular business provides a....
ALPHA MOS : Communiqué normé - Cible
COMMUNIQUE RELATIF AU DEPOT D'UN PROJET DE NOTE EN REPONSE A L'OFFRE PUBLIQUE D'ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETE
Alpha MOS
INITIEE CONJOINTEMENT PAR
Jolt capital
Ambrosia....
5 of the Most Hated Biotech Stocks on the Market: Are They Buys?
One of the best ways to measure how much a stock is hated is by looking at the percentage of the stock's float that's sold short. Short-sellers think so poorly of a stock that they're willing to....